Effort to legalize hemp gains new life in Kentucky

posted in: Latest Hemp News 0

 

3 types cannabis

 

Gregory A. Hall, The (Louisville, Ky.) Courier-Journal

FRANKFORT, Ky. — With support from some of the state’s top politicians and claims that it would create thousands of jobs, an effort to legalize industrial hemp — the less-potent cousin of marijuana — may have its best chance of passing the Kentucky General Assembly.

Opposition from the Kentucky State Police helped kill earlier efforts to legalize hemp, which can be processed into fiber for clothing or provide an oil used in skin- and hair-care products. Once legal, hemp production in the United States was centered in Kentucky. Production fell nationally after the mid-1800s, as cotton surged.

State police still oppose legalizing hemp, arguing in part that because the plants look virtually the same as marijuana it could impede drug enforcement efforts.

But the proposal to legalize hemp has gained momentum from the alliance of Kentucky Agriculture Commissioner James Comer, state Senate Agriculture Committee Chairman Paul Hornback, U.S. Sen. Rand Paul and the Kentucky Chamber of Commerce.

"This is something that you don’t have to borrow any money (for) that will have an immediate impact of thousands of jobs," Comer said, based on an assumption that processors and manufacturers would locate in Kentucky if it is one of the first states to approve it. "We’re ahead at something that relates to economic development for once, so let’s pursue it."

Comer and Paul say the state police concerns are unfounded because growers of industrial hemp would be licensed and global-positioning system devices would identify legal crops and reveal others as illegal.

Comer’s Senate Bill 50, sponsored by Hornback, a Republican from Shelbyville, was filed earlier this month just before the legislature adjourned until February.

The bill would require growers to be licensed annually and have their backgrounds checked by the Agriculture Department. Each licensee would be required to plant a minimum of 10 acres to eliminate people who aren’t serious from getting licenses.

Growers would have to keep sales contracts for three years and provide names of hemp buyers to the department.

Hemp seeds produce plants with less than 1 percent THC, the active ingredient in marijuana, which has between 3 percent and 15 percent THC.

Comer said he believes there are 22 votes in the 38-member Senate in favor of the bill. But if it isn’t assigned to Hornback’s committee by Senate President Robert Stivers and other Senate leaders, it may never get to the floor.

"I’m afraid I see problems in the Senate," Comer said.

Stivers, a Republican from Manchester, said some members are uncomfortable with the bill.

If the measure passes the Senate, it likely will face an even tougher battle in the House, where Agriculture Committee Chairman Tom McKee, a Democrat from Cynthiana, has blocked similar bills from getting a vote in the past

McKee has said the state police concerns resonate with him.

"I think we have some questions to answer, but I certainly don’t want to close any opportunity for viable agriculture," McKee said earlier this month.

Gov. Steve Beshear said on a Lexington radio call-in show recently that his "only hesitation" is law enforcement concerns.

Even if an industrial hemp bill passed in Kentucky, it would still need federal approval. Federal drug policy effectively bans growing it, although other countries, such as Canada, allow it.

Paul, a Bowling Green Republican, has supported federal legislation to enable hemp production by classifying it separately from marijuana. Paul and Comer appeared together at the Kentucky State Fair last year to talk about their support for industrial hemp.

If legalized, Comer said he doesn’t see corn and soybean growers in Western Kentucky switching to industrial hemp, but he said it would be a profitable alternative for growers in hillier areas whose land is now used for grazing and pasture.

CONTINUE READING…

Ky. hemp supporters gain big endorsement

posted in: Latest Hemp News 0

Published: January 20, 2013

By BRUCE SCHREINER — Associated Press

LOUISVILLE, Ky. — Industrial hemp’s repositioning toward mainstream status gained ground with a timely endorsement from the Kentucky Chamber of Commerce. But the plant’s proponents have more work to do in cultivating support to legalize a crop that once was a Bluegrass state staple.

 

http://3.bp.blogspot.com/-h8gfyIbtXGM/UAx1yxp4kjI/AAAAAAAAAoU/bG5ez3J9ZJE/s1600/Hemp+-+Kentucky+Hemp+Coalition.jpg

 

 

The chamber said recently that provided there’s adequate regulatory oversight, it supports legislation to position Kentucky as a leader in the production and commercialization of industrial hemp. The position was hailed by hemp backers, noting the chamber’s political clout.

"When Kentucky’s leading voice for small businesses and economic development endorses a piece of legislation, lawmakers sit up and listen," said state Agriculture Commissioner James Comer, a former state lawmaker.

Comer is leading the comeback campaign for the versatile crop outlawed for decades due to its association with its cousin, marijuana. Hemp has a negligible content of THC, the psychoactive compound that gives marijuana users a high.

Comer, a farmer himself, touts hemp’s potential while crisscrossing the state, saying Kentucky can become a hub of hemp production and manufacturing. The crop can be turned into paper, clothing, food, biofuel, lotions and other products.

"We could be the Silicon Valley of industrial hemp manufacturing right here in Kentucky," Comer said recently.

Bills aimed at legalizing the crop have been introduced in the Kentucky House and Senate, and lawmakers are expected to debate the issue when they return to the State Capitol in Frankfort next month to resume the 2013 session.

But hemp backers acknowledge challenges remain, namely resistance from Kentucky State Police. And that opposition could have a spillover effect with lawmakers hesitant to oppose the state’s top law enforcement agency.

State Police Commissioner Rodney Brewer last month restated the agency’s opposition, saying law enforcement may have difficulty distinguishing between hemp and marijuana.

Comer met with Brewer following a meeting of the Kentucky Industrial Hemp Commission late last year, but the commissioner said they’ve had no follow-up discussions. Comer said he’d like to have state police support but sees the agency’s resistance as a "non-factor."

"I was a state representative for 11 years and very few bills ever passed without somebody being opposed to them," he said.

Republican Sen. Paul Hornback of Shelbyville, lead sponsor of one of the hemp bills, said state police opposition will be an obstacle. But he said the state chamber’s support for legalizing the crop helps reshape the crop’s image.

"Everybody has to feel comfortable with the bill," said Hornback, a tobacco farmer who once was lukewarm to hemp. "With the stature that the state chamber has, I think it does legitimize it. It brings credibility to the issue."

Supporters say there’s a ready-made market for hemp, pointing to industry estimates that U.S. retail sales of hemp products exceed $400 million. Hemp is grown legally in Canada and many other countries, and imports into the U.S. include finished hemp products.

At least a couple of Kentucky companies – a tobacco processor and a seed supplier – have expressed interest in branching out into hemp. Hemp supporters say that could lead to jobs, especially in rural areas.

But the resistance of state police could be a sticking point for some lawmakers, including the top House leader.

"It will be difficult to pass any legislation that doesn’t have the support of the Kentucky State Police and Kentucky’s law enforcement community," said House Speaker Greg Stumbo, D-Prestonsburg. "As long as they have reservations, I have reservations."

Another potentially key player in the debate, Rep. Tom McKee, D-Cynthiana, said the biggest impediments to hemp’s comeback are the federal ban on hemp and the concerns of state police.

But McKee, chairman of the House Agriculture and Small Business Committee, hasn’t yet staked out a position on the issue.

"We don’t want to close a door on any viable agricultural crop that is profitable and would be well-accepted," he said.

Under Hornback’s bill, hemp growers would need licenses, and applicants would have to pass criminal background checks.

U.S. Sen. Rand Paul said he would seek a waiver from the federal ban on hemp for Kentucky if state lawmakers vote to legalize the crop. Paul also has pushed for federal legislation to remove restrictions on hemp cultivation. The Kentucky Republican said hemp supporters need to persuade law enforcement skeptics that the crop "won’t make the drug problem worse."

"We live in a modern world where we have GPS," he said in a recent speech in Frankfort. "Couldn’t a farmer or anybody who wants to grow it just get a simple one-page permit and say these are my GPS coordinates where it’s being grown and it could be checked?"

As for Comer, the agriculture commissioner has said he won’t defy the federal government on the issue.

The crop hasn’t been grown in the U.S. since the 1950s. Kentucky once was a leading producer of industrial hemp. During World War II, the U.S. government encouraged farmers to grow hemp for the war effort because other industrial fibers, often imported from overseas, were in short supply.

Because it can thrive in small, sloping plots, Comer said hemp could be a viable crop on marginal land in central and eastern Kentucky.

"A decade from now, someone will look back and think, ‘You mean there were people opposed to growing industrial hemp?’" he said.

Read more here: http://www.kentucky.com/2013/01/20/2483327/hemp-supporters-gain-big-endorsement.html#storylink=cpy

If You Smoke It, You Will Become Addicted!

posted in: Cannabis News 1

In recent weeks, we have seen a shift in how drug war proponents are talking about marijuana. No longer able to convince the public that people who use marijuana should go to jail, they are singing a new tune; they should all go to treatment. This is a shift we have seen before. When marijuana first came on the scene in the U.S. in the early 1900s, reports of marijuana induced violence among Mexicans fueled the nation’s fear about the little known plant. When the general population started experimenting with the herb in the 1920s, it became clear that the claims of violence were fabricated. Losing the ability to instill fear in the public around marijuana use, the message was modified. The new message tied marijuana use to insanity and mental illness, which were highly stigmatized conditions, and continue to be. Being labeled as mentally ill frightened the white, middle class, marijuana consumers, and this fear led to the support of the Marijuana Tax Act in 1937.

Fast forward to 2012. Public support for marijuana legalization is at an all-time high and the government acknowledges that a change is being considered. No longer able to convince Americans that marijuana consumers are dangerous criminals who deserve to be locked up, history is repeating itself. We are seeing a shift in the message, from marijuana consumers as criminals to marijuana consumers as sick people who belong in treatment. It’s a propaganda shell game and we can’t fall for it again.

A recent article in the New York Times quoted Dr. Nora Volkow, the head of the National Institute on Drug Abuse as saying that 1 out of 6 adolescents who try marijuana will become addicted. That is akin to saying, if you keep making that face, it will freeze that way. In fact, a mere 2.8% of 12-17 year olds who used marijuana in 2010 entered treatment for it, and many of those cases could be the result of an agreement between the courts and the defendant in lieu of involvement with the juvenile justice system. When looking at the broader landscape of marijuana use, we see that 1.1% of marijuana users 12 and older in 2010 went to treatment for the substance. We also saw twice as many arrested for simple marijuana possession that year than enter treatment for marijuana dependence (750,000 vs. 335,833). The claim that marijuana causes mental illness, or that all marijuana consumers are addicted and in need of treatment undermines the efforts by mental health and addictions professionals to address the serious illnesses and addictions that pose real threats to persons and society.

Dr. David Nathan, a clinical associate professor at Robert Wood Johnson Medical School and recently elected as a distinguished fellow in the American Psychiatric Association, wrote in a piece on CNN.com, “Throughout my career as a clinical psychiatrist, I have seen lives ruined by drugs like cocaine, painkillers and alcohol. I have also borne witness to the devastation brought upon cannabis users — almost never by abuse of the drug, but by a justice system that chooses a sledgehammer to kill a weed.”

Recently, former Rhode Island Congressman Patrick Kennedy announced the formation of a new group, SAM, which stands for A Smarter Approach to Marijuana. Kennedy and his group recognize that the argument of jail for marijuana is no longer salient with today’s population, so they have repackaged the message for a new generation: marijuana use is a mental illness and requires treatment, every time. This sentiment is echoed in his group’s project list, which includes, “Increased funding for mental health courts and treatment of drug dependency, so those caught using marijuana might avoid incarceration, get help and potentially have their criminal records cleared.”

On its face, this statement is not so outrageous, but upon closer look it is frightening for two reasons. First, although increased funding for mental health services and substance abuse treatment can be beneficial, according to a 2008 report, 90% of those who currently need substance abuse treatment do not receive it, this compares to 24% of diabetes patients who do not receive treatment. It is estimated that 23 million people need addiction care, and only 2.3 million receive it. Forcing marijuana consumers into an already overloaded system will reduce the likelihood of care for those with serious, life threatening addictions. Furthermore, since approximately 37% of treatment referrals come from the criminal justice system, initiating a pipeline from the courtroom to treatment will result in a tidal wave of first time, young marijuana offenders entering substance abuse treatment to trade the label of criminal for addict. Secondly, Kennedy’s group refers to treatment for those “caught” with marijuana. This implies, that, under his plan, the U.S. will continue to seek out marijuana users, presumably via law enforcement. Or, perhaps Kennedy et al will institute a special marijuana task force charged with roaming the country in search of marijuana addicts. Whatever the case, SAM’s plan involves the active identification of marijuana consumers, followed by forced involvement in the system. Don’t be fooled, this is not a “new way” for marijuana, but rather a regressive old approach dressed in new clothes.

Source: Huffington Post (NY)
Author: Amanda Reiman, Policy Manager, Drug Policy Alliance
Published: January 18, 2013
Copyright: 2013 HuffingtonPost.com, LLC
Contact: [email protected]
Website: http://www.huffingtonpost.com/

Studying Marijuana and Its Loftier Purpose

posted in: Latest Hemp News 0

Tikkun Olam, a medical marijuana farm in Israel, blends the high-tech and the spiritual.

By ISABEL KERSHNER
Published: January 1, 2013

 

SAFED, Israel — Among the rows of plants growing at a government-approved medical marijuana farm in the Galilee hills in northern Israel, one strain is said to have the strongest psychoactive effect of any cannabis in the world. Another, rich in anti-inflammatory properties, will not get you high at all.

Marijuana is illegal in Israel, but farms like this one, at a secret location near the city of Safed, are at the cutting edge of the debate on the legality, benefits and risks of medicinal cannabis. Its staff members wear white lab coats, its growing facilities are fitted with state-of-the-art equipment for controlling light and humidity, and its grounds are protected by security cameras and guards.

But in addition to the high-tech atmosphere, there is a spiritual one. The plantation, Israel’s largest and most established medical marijuana farm — and now a thriving commercial enterprise — is imbued with a higher sense of purpose, reflected by the aura of Safed, an age-old center of Jewish mysticism, as well as by its name, Tikkun Olam, a reference to the Jewish concept of repairing or healing the world.

There is an on-site synagogue in a trailer, a sweet aroma of freshly harvested cannabis that infuses the atmosphere and, halfway up a wooded hillside overlooking the farm, a blue-domed tomb of a rabbinic sage and his wife.

In the United States, medical marijuana programs exist in 18 states but remain illegal under federal law. In Israel, the law defines marijuana as an illegal and dangerous drug, and there is still no legislation regulating its use for medicinal purposes.

Yet Israel’s Ministry of Health issues special licenses that allow thousands of patients to receive medical marijuana, and some government officials are now promoting the country’s advances in the field as an example of its pioneering and innovation.

“I hope we will overcome the legal obstacles for Tikkun Olam and other companies,” Yuli Edelstein, the minister of public diplomacy and diaspora affairs, told journalists during a recent government-sponsored tour of the farm, part of Israel’s effort to brand itself as something beyond a conflict zone. In addition to helping the sick, he said, the effort “could be helpful for explaining what we are about in this country.”

Israelis have been at the vanguard of research into the medicinal properties of cannabis for decades.

In the 1960s, Prof. Raphael Mechoulam and his colleague Yechiel Gaoni at the Weizmann Institute of Science isolated, analyzed and synthesized the main psychoactive ingredient in the cannabis plant, tetrahydrocannabinol, or THC. Later, Professor Mechoulam deciphered the cannabinoids native to the brain. Ruth Gallily, a professor emerita of immunology at the Hebrew University of Jerusalem, has studied another main constituent of cannabis — cannabidiol, or CBD — considered a powerful anti-inflammatory and anti-anxiety agent.

When Zach Klein, a former filmmaker, made a documentary on medical marijuana that was broadcast on Israeli television in 2009, about 400 Israelis were licensed to receive the substance. Today, the number has risen to about 11,000.

Mr. Klein became devoted to the subject and went to work for Tikkun Olam in research and development. “Cannabis was used as medicine for centuries,” he said. “Now science is telling us how it works.”

Israeli researchers say cannabis can be beneficial for a variety of illnesses and conditions, from helping cancer patients relieve pain and ease loss of appetite to improving the quality of life for people with post-traumatic stress disorder and neuropsychological conditions. The natural ingredients in the plant, they say, can help with digestive function, infections and recovery after a heart attack.

The marijuana harvest, from plants that can grow over six feet tall, is processed into bags of flowers and ready-rolled cigarettes. There are also cannabis-laced cakes, cookies, candy, gum, honey, ointments and oil drops. The strain known as Eran Almog, which has the highest concentration of THC, is recommended for severe pain. Avidekel, a strain rich in CBD and with hardly any psychoactive ingredient, allows patients to benefit from the drug while being able to drive and to function at work.

Working with Hebrew University researchers, the farm has also developed a version in capsule form, which would make exporting the drug more practical, should the law allow it.

CONTINUE READING PAGE 2….

Colorado Preps for Recreational Marijuana

posted in: Cannabis News 0

Driving east on Interstate 70 through Denver’s warehouse district, the smell of the marijuana plants growing inside unmarked industrial buildings blasts through car air vents and overwhelms drivers who roll down their windows. The smell is a pungent reminder that the state of Colorado is now home to some of the world’s laxest marijuana regulations.

The state legalized medicinal marijuana use in 2000, but in November voters in Colorado went even further by approving a constitutional amendment that legalizes recreational marijuana for all users over 21 and aims to “regulate marijuana like alcohol.”

Now, a governor-appointed “Amendment 64” task force is racing to draft regulations on everything from banking to public safety, to submit to the governor and the general assembly by the end of February. The legal sale of marijuana to recreational users is scheduled to begin as early as October.

The passage of the new law raises a lot of questions, especially for the established medical marijuana community. While marijuana advocates cheered Amendment 64’s passage, Colorado’s current medical marijuana providers, arguably the nation’s most successful and well-regulated, are apprehensive about how the new laws might change the current landscape. These businesses, 299 medical marijuana centers statewide at the end of 2012, have completed 1000-page business applications and probing background checks, paid taxes to the state Department of Revenue and still managed to turn a profit.

Now that recreational marijuana is legal, medical marijuana sellers must decide whether to pursue a permit to serve recreational users, or remain medical dispensaries. If they do expand their operations, how might the new recreational market change their relationship with their medical patients? And most importantly, will the federal government shut them down as soon as they begin serving recreational users?

Established Medical Marijuana Market

When it comes to regulating marijuana, Colorado is further along than the state of Washington, which also legalized recreational marijuana use in November’s election. In Colorado, unlike in Washington, medical marijuana dispensaries are for-profit businesses and all dispensaries and employees are registered and licensed, which has helped legitimize an industry that’s been forced underground in most of the world. You won’t see marijuana leaves emblazoned on dispensary doors or pictures of Bob Marley on the walls. Instead, they feel like small doctors’ offices with waiting rooms and helpful receptionists.

“We’re trying to rebrand the image of marijuana in general and get away from that pot stoner culture,” says Jason Katz, head of operations at Local Product, a Denver dispensary located in view of the statehouse. “As long as we can continue to keep doing that with the recreational model…we’ll be moving in the right direction.”

For most medical marijuana sellers, the decision to serve recreational users is likely to come down to economics—there will simply be more customers, and more money, for businesses who serve recreational users alongside medical users.

“If anyone over 21 can buy marijuana,” says Katz, “why would a patient go through a $100 state registration process to get a medical marijuana card when they can just buy it without doing any of that? I think it makes sense for our business to go recreational in that it will open up our customer base.”

Analysts expect that customer base to be upwards of one million in-state consumers, which for a marijuana products manufacturing company like Denver-based Dixie Elixirs, spells big profits.

“Ultimately my goal is to sell our business to big alcohol, big tobacco, or potentially big pharma,” says Tripp Keber, managing director of Dixie Elixirs. The company makes more than 75 marijuana-infused products, ranging from marijuana-infused truffles to flavored sodas to non-psychoactive cannabis body lotion. Located in the Denver warehouse district , a whiff of the outside air leaves little doubt about the new cash crop in town.

But until the regulations are finalized later this year, business owners who want recreational permits will have to sit on their hands. They’ll have to make sure they follow all the rules, such as not selling to anyone without a medical marijuana card, says Denver medical marijuana lawyer Warren Edson. That takes a lot of restraint. Since Amendment 64’s passage, says Katz, he’s had about three or four people a day either calling or knocking on the door of his dispensary asking to buy recreational marijuana.

Writing The Rules

In a dimly-lit room in a Denver office building across the street from the golden-domed statehouse, the first draft of the new rules for recreational marijuana are being hammered out by agency officials, medical marijuana interest groups, lawyers, doctors and concerned citizens. The mundaneness of the setting belies the enormity of the task: creating the most open marijuana market in the country while at the same time protecting public health, safety and trying not to run too far afoul of the federal government, which still considers marijuana use—medical or otherwise—to be illegal.

At a working group meeting of the Amendment 64 task force last week, banking issues took center stage. Under the Controlled Substances Act, any bank that takes money from an illegal enterprise can lose its FDIC coverage and potentially be prosecuted. This means that medical marijuana businesses are cash only, which makes for a potentially dangerous situation where businesses have thousands of dollars in cash on hand at any given time, making them vulnerable to robbers.

But fixing this problem would require action from the federal government, which is unlikely in such a short amount of time. However, the attitudes in Washington, D.C. about marijuana seem to be tacitly on the side of state experimentation.

The Obama administration is taking a hands-off approach in both Colorado and Washington, saying his administration has “bigger fish to fry” than going after recreational marijuana users in those states. And a 2009 U.S. Department of Justice memo made clear that pursuing medical marijuana users would be the administration’s lowest enforcement priority.

That bodes well for Colorado, since its strict medical marijuana regulations seem to have satisfied federal drug enforcement authorities. Few Colorado dispensaries have been shut down and raids are uncommon, unlike in California where the Drug Enforcement Agency has raided and closed hundreds of dispensaries in the last few years. Many in the medical marijuana community hope that the Amendment 64 task force and ultimately the general assembly simply roll over many of the medical marijuana regulations into new recreational regulations.

The regulations also make business owners and employees feel safer navigating this legally precarious industry. Other states such as Massachusetts, Arizona, Connecticut that are crafting their own medical marijuana regulations are looking to Colorado’s example as a way to serve patients while not upsetting the federal government.

A Marijuana Trajectory

Indeed, national political analysts agree that Colorado’s trajectory, from making marijuana possession the lowest criminal priority, to legalizing medical marijuana and then legalizing recreational use, is the ultimate goal for most activists. “I don’t think the distinction between medical and recreational marijuana will hold up,” says Allen St. Pierre, executive director of the National Association for the Reform of Marijuana Laws (NORML). “We hear people asking, why be in purgatory? Why spend 10 years on decriminalizing possession and medical marijuana only to move on to recreational later?… Legalization is so much more politically salient now that it makes the discussion around medical marijuana almost pedestrian.”

Already this legislative session, legislators in five states have proposed medical marijuana legislation and in five other states, legislators will consider following in Colorado and Washington’s footsteps to regulate marijuana like alcohol, according to the Marijuana Policy Project.

But however the states regulate it, marijuana remains a Schedule I narcotic in the eyes of the federal government, equivalent to heroin and LSD. That means that, while unlikely, all of these business owners, employees, and even regulators are open to federal prosecution. While the risks are still high, Keber says he sleeps pretty soundly.

“We operate with our doors wide open,” says Keber, “and we’ve hosted law enforcement officers, state and federal legislators here. The reality is that (prosecution) is always a concern, but I don’t lose sleep over it. If federal agents arrest me… they should go to mayor’s office since he puts his name on the business license, then they should wrap up the governor since he signed it into law.”

Source: Stateline.org (DC)
Author: Maggie Clark, Staff Writer
Published: January 16, 2013
Copyright: 2013 Stateline.org
Contact: [email protected]
Website: http://www.stateline.org/

In California, It’s U.S. vs. State Over Marijuana

posted in: Cannabis News 0

Matthew R. Davies graduated from college with a master’s degree in business and a taste for enterprise, working in real estate, restaurants and mobile home parks before seizing on what he saw as uncharted territory with a vast potential for profits — medical marijuana.

He brought graduate-level business skills to a world decidedly operating in the shadows. He hired accountants, compliance lawyers, managers, a staff of 75 and a payroll firm. He paid California sales tax and filed for state and local business permits.

But in a case that highlights the growing clash between the federal government and those states that have legalized marijuana for medical or recreational use, the United States Justice Department indicted Mr. Davies six months ago on charges of cultivating marijuana, after raiding two dispensaries and a warehouse filled with nearly 2,000 marijuana plants.

The United States attorney for the Eastern District of California, Benjamin B. Wagner, a 2009 Obama appointee, wants Mr. Davies to agree to a plea that includes a mandatory minimum of five years in prison, calling the case a straightforward prosecution of “one of the most significant commercial marijuana traffickers to be prosecuted in this district.”

At the center of this federal-state collision is a round-faced 34-year-old father of two young girls. Displaying a sheaf of legal documents, Mr. Davies, who has no criminal record, insisted in an interview that he had meticulously followed California law in setting up a business in 2009 that generated $8 million in annual revenues. By all appearances, Mr. Davies’ dispensaries operated as openly as the local Krispy Kreme, albeit on decidedly more tremulous legal ground.

“To be looking at 15 years of our life, you couldn’t pay me enough to give that up,” Mr. Davies said at the dining room table in his two-story home along the San Joaquin River Delta, referring to the amount of time he could potentially serve in prison. “If I had believed for a minute this would happen, I would never have gotten into this.

“We thought, this is an industry in its infancy, it’s a heavy cash business, it’s basically being used by people who use it to cloak illegal activity. Nobody was doing it the right way. We thought we could make a model of how this should be done.”

His lawyers appealed this month to Attorney General Eric H. Holder Jr. to halt what they suggested was a prosecution at odds with Justice Department policies to avoid prosecutions of medical marijuana users and with President Obama’s statement that the government has “bigger fish to fry” than recreational marijuana users.

“Does this mean that the federal government will be prosecuting individuals throughout California, Washington, Colorado and elsewhere who comply with state law permitting marijuana use, or is the Davies case merely a rogue prosecutor out of step with administration and department policy?” asked Elliot R. Peters, one of his lawyers.

“This is not a case of an illicit drug ring under the guise of medical marijuana,” Mr. Peters wrote. “Here, marijuana was provided to qualified adult patients with a medical recommendation from a licensed physician. Records were kept, proceeds were tracked, payroll and sales taxes were duly paid.”

Mr. Holder’s aides declined to comment, referring a reporter to a letter from Mr. Wagner to Mr. Davies’s lawyers in which he disputed the depiction of the defendant as anything other than a major-league drug trafficker.

“Mr. Davies was not a seriously ill user of marijuana nor was he a medical caregiver — he was the major player in a very significant commercial operation that sought to make large profits from the cultivation and sale of marijuana,” the letter said. Mr. Wagner said that prosecuting such people “remains a core priority of the department.”

The case illustrates the struggle states and the federal government are now facing as they seek to deal with the changing contours of marijuana laws and public attitudes toward the drug. Colorado and Washington legalized marijuana for recreational use last year, and are among the 18 states, and the District of Columbia, that currently allow its medical use.

Two of Mr. Davies’s co-defendants are pleading guilty, agreeing to five-year minimum terms, to avoid stiffer sentences. Mr. Davies, while saying he did not “want to be a martyr,” decided to challenge the indictment with a combination of legal and public-relations measures, setting up a Web site devoted to his case and hiring Chris Lehane, a hard-hitting political consultant and former senior aide in Bill Clinton’s White House.

Among Mr. Davies’s advocates here in California are Paul I. Bonell, who was the president of the Premier Credit Union for 21 years before Mr. Davies hired him in early 2011 to oversee his businesses’ fiscal controls. After the businesses were raided in October that year, Mr. Bonell took a position as the head of the Lodi Boys and Girls Club.

“I had some reservations going in,” he said of Mr. Davies’s enterprise. “But the industry was exploding. Matt wanted to have internal controls in place. And we thought: This was a legitimate business. If the State of California deems it legitimate, we want to be the best at it.”

Mr. Davies’s accountant, David M. Silva, said he set up spreadsheets to keep track of inventories, revenues and expenses. “I’ve been a C.P.A. for 30 years,” Mr. Silva said. “What I saw was a guy who was trying to run an operation in an up-and-up way.”

The federal authorities said they stumbled across the operation after two men were spotted apparently breaking into Mr. Davies’s 30,000-square-foot Stockton warehouse. The police said they smelled marijuana plants. Federal agents conducted a raid and confiscated 1,962 plants and 200 pounds of marijuana.

Mr. Davies, who is free on $100,000 bail, greeted visitors to his gated home by asking them to speak softly while walking through the entryway so as not to awaken his sleeping infant. He called out to his wife when asked when he was indicted: “Hey, Molly — we were indicted on your birthday, right? July 18.”

Mr. Davies referred to marijuana as “medicine,” and himself as a turnaround expert.

“We were basically pharmacists for medical marijuana — everything was in full compliance with state law,” he said. “We paid our employees. We paid overtime. We had people going for unemployment if we fired them.”

“Why are they coming after me?” he asked. “If they have such a problem with California, why can’t they sue California?”

Stephanie Horton, 25, who went to work for Mr. Davies after going to one of his dispensaries to obtain medical marijuana to help her deal with ovarian and cervical cancer, said she was devastated by the arrest of employers she described as among the best she had ever had — not to mention the loss of her job.

“I’d go back and work there in a heartbeat,” Ms. Horton said. “I totally trusted them. We’re not criminals. I’ve never been arrested my whole life. I need that medication, and so do a whole lot of people.”

But federal prosecutors offered a much less sympathetic view of Mr. Davies. The authorities shut down the warehouse and two dispensaries but said that Mr. Davies had ties to a total of seven dispensaries in the region, which they said yielded $500,000 in annual profits. Mr. Davies’s lawyers disputed those assertions.

“Mr. Davies is being prosecuted for serious felony offenses,” Mr. Wagner wrote to Mr. Davies’s lawyers. “I understand he is facing unpleasant alternatives. Neither a meeting with me nor seeking a review in Washington will change that reality.”

This is as much a legal clash as a cultural clash. Recreational marijuana use is common across this state, and without the legal stigma attached to it in much of the country. The federal government is viewed as a distant force.

“It’s mind-boggling that there were hundreds of attorneys advising their clients that it was O.K. to do this, only to be bushwhacked by a federal system that most people in California are not even paying attention to,” said William J. Portanova, a former federal drug prosecutor and a lawyer for one of Mr. Davies’s co-defendants. “It’s tragic.”

A version of this article appeared in print on January 14, 2013, on page A1 of the New York edition with the headline: In California, It’s U.S. vs. State Over Marijuana.

Source: New York Times (NY)
Author: Adam Nagourney
Published: January 14, 2013
Copyright: 2013 The New York Times Company
Contact: [email protected]
Website: http://www.nytimes.com/

Kentucky agriculture commissioner brings pro-hemp message to Lexington

posted in: Latest Hemp News 0

 

hemp-300x200

 

 

Published: January 3, 2013

By Beverly Fortune — [email protected]

Kentucky Agriculture Commissioner James Comer brought his pro-hemp message to the Lexington Forum on Thursday.

Since taking office in 2011, Comer has held town meetings in all 120 Kentucky counties, inviting local legislators to attend, to promote industrial hemp. In the early 19th century, Kentucky was the nation’s leading hemp producer.

Comer is backing a bill in the General Assembly that would permit industrial hemp to again be cultivated.

Hemp would produce income for farmers and create manufacturing jobs for products using hemp, he said.

Farmers growing hemp would have to be licensed by the state and their fields inspected regularly, Comer said.

The Department of Agriculture, the state’s largest regulatory agency, would oversee cultivation and sales of the crop.

Hemp is a sustainable, annual crop that "is easy and cheap to grow," he said. "It grows well in this climate and requires very little fertilizer or insecticides." The plant grows best in marginal soils found in many Central and Eastern Kentucky counties.

For people, including law enforcement officers, who are concerned that marijuana might be grown in hemp fields and the hemp and marijuana plants confused, Comer said the two look completely different.

Marijuana is a short, bushy plant with lots of leaves; industrial hemp is tall, with a thick stalk and few leaves.

When grown near each other, hemp and marijuana cross-pollinate, and the hemp destroys buds on the marijuana plants, he said. "Industrial hemp is an enemy of marijuana," Comer said. "Law enforcement should be for industrial hemp."

The long-dormant Industrial Hemp Commission, revived under Comer, has contracted with the University of Kentucky College of Agriculture to conduct an economic-impact study.

For the crop to be grown successfully, there has to be a market for the fibers, Comer said. "Many products we make from plastic, like car dashboards, armrests, carpet and fabrics, are made from hemp in other countries. Hemp is also used to make paper."

Comer said one major benefit of growing hemp would be the manufacturing jobs created to produce items using hemp fibers, seed and oil.

"The United States is the only industrial country in the world that doesn’t allow industrial hemp to be grown, yet many products Americans buy have hemp as an ingredient," he said. Hemp is legally grown in Canada and China, and throughout Europe.

If the General Assembly approves growing industrial hemp, the federal government would have to lift restrictions before it could be grown. "I want us to be ready when the federal government gives the go-ahead. I’m convinced they’re going to do that," Comer said.

Beverly Fortune: (859) 231-3251. Twitter: @BFortune2010.

Read more here: http://www.kentucky.com/2013/01/03/2463466/state-agriculture-commissioner.html#storylink=cpy

Support The Industrial Hemp Farming Act

posted in: Latest Hemp News 0

Lawmakers in both the House of Representatives and the Senate are seeking to allow for the commercial farming of industrial hemp by introducing the Industrial Hemp Farming Act.

House Bill 1831, which was introduced last year by Texas Republican Ron Paul and a coalition of 25 co-sponsors, and SB 3501, introduced this August in the Senate by Oregon Democrat Ron Wyden and three co-sponsors, would exclude low potency varieties of marijuana from federal prohibition. If approved, this measure will grant state legislatures the authority to license and regulate the commercial production of hemp as an industrial and agricultural commodity. Several states — including North Dakota, Montana, and Vermont — have enacted regulations to allow for the cultivation of hemp under state law. However, none of these laws can be implemented without federal approval. Passage of HR 1831 would remove existing federal barriers and allow states that wish to regulate commercial hemp production the authority to do so.

Vote Hemp President, Eric Steenstra stated, "It is due time for the Senate as well as President Obama and the Attorney General to prioritize the crop’s benefits to farmers and to take action like Rep. Paul and the cosponsors of H.R. 1831 have done. With the U.S. hemp industry valued at over $400 million in annual retail sales and growing, a change in federal policy to allow hemp farming would mean instant job creation, among many other economic and environmental benefits."

According to a 2010 Congressional Resource Service report, "approximately 30 countries in Europe, Asia, and North and South America currently permit farmers to grow hemp." But the United States does not. As a result, U.S. companies that specialize in hempen goods have no choice but to import hemp material. These added production costs are then passed on to the consumer who must pay artificially high retail prices for hemp products.

Previous versions of The Industrial Hemp Farming Act have been introduced in the House, but failed to receive a public hearing or a committee vote. This is the first year the issue has ever been introduced in the Senate. Please write your members of Congress today and tell them to end the federal prohibition of industrial hemp production. For your convenience, a prewritten letter will be e-mailed to your member of Congress when you enter your contact information below. For more information about industrial hemp, please visit: http://www.votehemp.org.

Thank you for assisting NORML’s federal law reform efforts.

Cancer of Corruption, Seeds of Destruction: The Monsanto GMO Whitewash

posted in: Latest Hemp News 1

By F. William Engdahl

Global Research, December 19, 2012

Because of the power vested in the EU Commission in Brussels, Belgium, with command over a space encompassing 27 nations with more than 500 million citizens and the largest nominal world gross domestic product (GDP) of 18 trillion US dollars, it’s perhaps no surprise in this era of moral promiscuity that powerful private lobby groups such as the tobacco industry, the drug lobby, the agribusiness lobby and countless others spend enormous sums of money and other favors—legal and sometimes illegal—to influence policy decisions of the EU Commission.

This revolving door of corrupt ties between powerful private industry lobby groups and the EU Commission was in full view recently with the ruling of the European Food Safety Administration (EFSA) trying to discredit serious scientific tests about the deadly effects of a variety of Monsanto GMO corn.

Cancer of Corruption

In September 2012, Food and Chemical Toxicology, a serious international scientific journal, released a study by a team of scientists at France’s Caen University led by Professor Gilles-Eric Seralini. Before publication the Seralini study had been reviewed over a four-month period by a qualified group of scientific peers for its methodology and was deemed publishable.

It was no amateur undertaking. The scientists at Caen made carefully-documented results of tests on a group of 200 rats over a two-year life span, basically with one group of non-GMO fed rats, a so-called control group, and the other a group of GMO-fed rats.

Significantly, following a long but finally successful legal battle to force Monsanto to release the details of its own study of the safety of its own NK603 maize (corn), Seralini and colleagues reproduced a 2004 Monsanto study published in the same journal and used by the European Food Safety Authority (EFSA) for its 2009 positive evaluation of NK603.

Seralini’s group based their experiment on the same protocol as the Monsanto study but, critically, were testing more parameters more frequently. And the rats were studied for much longer—their full two year average life-time instead of just 90 days in the Monsanto study. The long time span proved critical. The first tumors only appeared 4 to7 months into the study. In industry’s earlier 90-day study on the same GMO maize Monsanto NK603, signs of toxicity were seen but were dismissed as “not biologically meaningful” by industry and EFSA alike. It seems they were indeed very biologically meaningful.

The study was also done with the highest number of rats ever measured in a standard GMO diet study. They tested also “for the first time 3 doses (rather than two in the usual 90 day long protocols) of the Roundup-tolerant NK603 GMO maize alone, the GMO maize treated with Roundup, and Roundup alone at very low environmentally relevant doses starting below the range of levels permitted by regulatory authorities in drinking water and in GM feed.” [1]

Their findings were more than alarming. The Seralini study concluded, “In females, all treated groups died 2–3 times more than controls, and more rapidly. This difference was visible in 3 male groups fed GMOs…Females developed large mammary tumors almost always more often than and before controls; the pituitary was the second most disabled organ; the sex hormonal balance was modified by GMO and Roundup treatments. In treated males, liver congestions and necrosis were 2.5–5.5 times higher. This pathology was confirmed by optic and transmission electron microscopy. Marked and severe kidney nephropathies were also generally 1.3–2.3 greater. Males presented 4 times more large palpable tumors than controls…” [2]

Four times meant four hundred percent more large tumors in GMO fed rats than in normally fed ones of the control group. Because rats are mammals, their systems should react to chemicals or, in this case GMO corn treated with Monsanto Roundup chemical herbicide, in a similar way to those of a human test subject. [3]

seeds_2.jpgIn their study the Seralini group further reported, “By the beginning of the 24th month, 50–80% of female animals had developed tumors in all treated groups, with up to 3 tumors per animal, whereas only 30% of controls [non-GMO-fed—w.e.] were affected. The Roundup treatment groups showed the greatest rates of tumor incidence with 80% of animals affected with up to 3 tumors for one female, in each group.” [4]

Such alarming results had not yet become evident in the first 90 days, the length of most all Monsanto and agrichemical industry tests to date, a clear demonstration of how important it was to conduct longer-term tests and apparently why the industry avoided the longer tests.

Seralini and associates continued to document their alarming findings: “We observed a strikingly marked induction of mammary tumors by R (Roundup) alone, a major formulated pesticide, even at the very lowest dose administered. R has been shown to disrupt aromatase which synthesizes estrogens (Richard et al., 2005), but to also interfere with estrogen and androgen receptors in cells (Gasnier et al., 2009). In addition, R appears to be a sex endocrine disruptor in vivo, also in males (Romano et al., 2010). Sex steroids are also modified in treated rats. These hormone-dependent phenomena are confirmed by enhanced pituitary dysfunction in treated females.” [5]

Roundup herbicide, by terms of the license contract with Monsanto, must be used on Monsanto GMO seeds. The seeds are in fact genetically “modified” only to resist the weed-killing effect of Monsanto’s own Roundup, the world’s largest-selling weed-killer.

In plain language, as another scientific study led by Prof. Seralini noted, “GMO plants have been modified to contain pesticides, either through herbicide tolerance or by producing insecticides, or both, and could therefore be considered as ‘pesticide plants’” [6]

Further, “Roundup Ready crops [such as Monsanto NK603 maize-w.e.] have been modified in order to become insensitive to glyphosate. This chemical, together with adjuvants in formulations, constitutes a potent herbicide. It has been used for many years as a weed killer…GMO plants exposed to glyphosate-based herbicides such as Roundup…can even accumulate Roundup residues throughout their life…Glyphosate and its main metabolite AMPA (with its own toxicity) are found in GMOs on a regular and regulatory basis. Therefore, such residues are absorbed by people eating most GMO plants (as around 80% of these plants are Roundup tolerant).” [7]

Suspiciously enough, Monsanto had repeatedly refused scientific requests to publish the exact chemicals used in its Roundup aside from one—glyphosate. They argued that it was a “trade secret.” Independent analyses by scientists indicated, however, that the combination of glyphosate with Monsanto’s “mystery” added chemicals created a highly toxic cocktail that was shown to toxically affect human embryo cells in doses far lower than used in agriculture.[8]

Mammary tumors that developed in rats fed GMO corn and/or low levels of Roundup. From the paper “Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize,” published in Food and Chemical Toxicology.

What was more than alarming in the context of Seralini’s first long-term independent study of the effects of a GMO diet on rats was that it took place some twenty years after US President George H.W. Bush gave the commercial release of GMO seeds the green light and mandated no government safety tests before release. Bush did so following a closed-door meeting with top officials of Monsanto Corporation, the world’s largest GMO concern.

The US President decreed then that GMO seeds were to be permitted in the United States with not one single independent precautionary government test to determine if they were safe for human or animal consumption. It became known as the Doctrine of Substantial Equivalence. The EU Commission dutifully aped the US Substantial Equivalence Doctrine of “hear no bad effects, see no bad effects…hear no evil, see no evil.”

EFSA ‘science’ exposed

What the Seralini study has set off has been the scientific equivalent of a thermonuclear explosion. It exposed the fact that the EU “scientific” controls on GMO were nothing other than accepting without question the tests given them by the GMO companies themselves. As far as the irresponsible bureaucrats of the EU Commission were concerned, when it came to GMO, the Monsanto fox could indeed “guard the hen house.”

Suddenly, with worldwide attention to the new Seralini results, clearly the EU Commission and its EFSA was under fire as never in their history and how they reacted was worthy of a bad copy of an Agatha Christie murder novel. Only it was no novel but a real-life conspiracy that  evidently involved some form of collusion between Monsanto and the GMO agrichemical cartel, EU commissioners, the GMO panel members of EFSA, complacent major media and several member governments of the EU, including Spain and Holland.

The Brussels EU scientific food regulatory organization, EFSA, was under the gun from the damning results of the long-term Seralini study. EFSA had recommended approval of Monsanto’s NK603 Roundup-tolerant maize in 2009 without first conducting or insuring any independent testing. They admitted in their official journal that they relied on “information supplied by the applicant (Monsanto), the scientific comments submitted by Member States and the report of the Spanish Competent Authority and its Biosafety Commission.” EFSA also admitted that the Monsanto tests on rats were for only 90 days. Seralini’s group noted that the massive toxic effects and deaths of GMO-fed rats took place well after 90 days, a reason why longer-term studied were obviously warranted. [9]

The Spanish report cited by EFSA was itself hardly convincing and was anything but independent. It stated, “according to the current state of scientific knowledge and after examining the existing information and data provided by the Monsanto Company, the Spanish Commission on Biosafety could give a favorable opinion to the commercialization in the EU of maize NK603…” And the scientific comments submitted by Member States seemed to include Spain and Holland which applied to license the Monsanto seed in the first place. [10]

The EFSA concluded at the time of its approval in 2009 that, “the molecular data provided [by Monsanto-w.e.] are sufficient and do not raise a safety concern.” The Brussels scientific panel further declared amid scientific-sounding verbiage that, “The EFSA GMO Panel is of the opinion that maize NK603 is as safe as conventional maize. Maize NK603 and derived products are unlikely to have any adverse effect on human and animal health in the context of the intended uses.” [11]

Now, in September 2012, three years after the commercial introduction of Monsanto GMO maize in the EU, Seralini showed, complete with ghastly photos, that Monsanto’s GMO maize demonstrably caused severe rates of cancerous tumors and early death in rats.

The EU Commission in Brussels had guidelines that were as revealing for what they did not say as for what they did say about what precautions are taken to insure public health and safety from exposure to GMO plants and their paired toxic herbicides: “Toxicological assessments on test animals are not explicitly required for the approval of a new food in the EU or the US. Independent experts have decided that in some cases, chemical analyses of the food’s makeup are enough to indicate that the new GMO is substantially equivalent to its traditional counterpart…In recent years, biotech companies have tested their transgenic products (maize, soy, tomato) before introducing them to the market on several different animals over the course of up to 90 days. Negative effects have not yet been observed.” [12]

Because of US Government arm-twisting and of the obviously powerful lobby power of the Monsanto-led GMO agrichemical lobby in the US and EU, as of the time of the Seralini study, no regulatory authority in the world had  requested mandatory chronic animal feeding studies to be performed for edible GMOs and formulated pesticides. The only studies available were a tiny handful of 90 day rat feeding trials carried out by the biotech industry and no studies longer than that, apparently on the principle that conflict of interest in an area as important as the safety of food should not be taken as a serious matter.

Revealingly, the EU stated publicly their seemingly reassuring policy: “GMO critics claim that feeding studies with authorized GMOs have revealed negative health effects. Such claims have not been based on peer-reviewed, scientifically accepted evaluations. If reliable, scientific studies were to indicate any type of health risk, the respective GMO would not receive authorization.” [13] That was the EU official line until the 2012 Seralini bomb exploded in their faces.

EU Commission deception, coverup

Seeds of DestructionThe September 2012 Seralini study was peer-reviewed, and it was published in a highly respected international scientific journal after such review. What was the response of the EU Commission and the EFSA? Nothing short of fraudulent deception and coverup of their corruption by the Monsanto GMO lobby.

On November 28, 2012, only a few weeks after the study was published, EFSA in Brussels issued a press release with the following conclusion: “Serious defects in the design and methodology of a paper by Séralini et al. mean it does not meet acceptable scientific standards and there is no need to re-examine previous safety evaluations of genetically modified maize NK603.”   Per Bergman, who led EFSA’s work, said: “EFSA’s analysis has shown that deficiencies in the Séralini et al. paper mean it is of insufficient scientific quality for risk assessment. We believe the completion of this evaluation process has brought clarity to the issue.” [14] Nothing could have been farther from the truth.

At the very minimum, the precautionary principle in instances involving even the potential for grave damage to the human population would mandate that the EU Commission and its EFSA should order immediate further serious, independent long-term studies to prove or disprove the results of the Seralini tests. That refusal to re-examine its earlier decision to approve Monsanto GMO maize, no matter what flaws might or might not have been in the Seralini study, suggested the EFSA might be trying to cover for the GMO agrichemical lobby at the very least.

Instead of clarity, the EFSA statement once more fed EFSA critics who had long argued that the scientists on EFSA’s GMO Panel had blatant conflicts of interest with the very GMO lobby they were supposed to regulate. Corporate Europe Observer, an independent EU corporate watchdog group noted about the EFSA response, “EFSA failed to properly and transparently appoint a panel of scientists beyond any suspicion of conflict of interests; and it failed to appreciate that meeting with Europe’s largest biotech industry lobby group to discuss GMO risk assessment guidelines in the very middle of a EU review undermines its credibility.” [15]

More damaging for the shoddy EFSA coverup on behalf of Monsanto was the fact that over half of the scientists involved in the GMO panel which positively reviewed the Monsanto’s study for GMO maize in 2009, leading to its EU-wide authorization, had conflicts of interests with the biotech industry.[16]

A report by Corporate Europe Observatory (CEO) found that more than half of the GMO panel experts who signed the approval had conflicts of interest.

The conflicts ranged from receiving research funding from the biotech industry, being a member or collaborator in a pro-biotech industry association, to writing or reviewing industry-sponsored publications. Some conflicts revealed a conflict of scientific interests, with some panel members involved in working on the creation of transgenic plants – including potatoes – with antibiotic-resistant marker genes – including nptII.[17]

Secondly, although none of EFSA’s GMO panel members were medical experts in the use of antibiotics in human medicine, they decided that neomycin and kanamycin were antibiotics with “no or only minor therapeutic relevance”. The World Health Organisation (WHO) classified these antibiotics as “critically important” in 2005.

Dutch scientist Harry Kuiper, chair of the EFSA GMO panel who had close links to the biotech industry, played a key role in the framing of this disputed key scientific advice.

Kuiper himself is an open advocate of less controls on GMO seed proliferation in the EU. He has led the EFSA GMO panel since 2003, during which time EFSA went from no GMO approvals to 38 GMO seeds approved for human consumption. The criteria for approval were developed by Kuiper for EFSA in cooperation with Monsanto and the GMO industry and a Monsanto pseudo-scientific front group called ILSI, the Washington-based International Life Sciences Institute, between 2001 and 2003. The board of the noble-sounding ILSI in 2011 was comprised of senior people from Monsanto, ADM (one of the world’s biggest purveyors of GMO soybeans and corn), Coca-Cola, Kraft Foods (major proponent of GMO in foods) and Nestle, another giant GMO food industry user. [18]

One critic of the blatant conflict of interest in having the top EU food safety regulator in bed with the industry whose practices he is mandated to objectively assess noted, “During that period, Harry Kuiper and Gijes Kleter (both members of the EFSA GMO Panel) were active within the ILSI Task Force as experts and as authors of the relevant scientific publications. It is a scandal that Kuiper has remained as Chair of EFSA’s GMO Panel since 2003, and that he is still Chair in spite of the massive criticism directed at the Panel from NGOs and even from the Commission and EU member states.” [19]

The brazen conflicts of interest between Monsanto and the agribusiness lobby and the EFSA went further. In May 2012 Professor Diána Bánáti was forced to resign as Chairman of the EFSA Management Board when it was learned she planned to take up a professional position at the Monsanto-backed International Life Sciences Institute (ILSI) in Washington. The same Diána Bánáti had been forced to resign, not as EFSA chairman but as a simultaneous Board Member of ILSI in 2010. Public interest groups made calls for her to resign from EFSA but to no avail. [20] At ILSI she will be able to use expertise and contacts gained from working for the EFSA to help GMO companies like Monsanto and other food industry companies influence policy across the world.

In sum, it came as no surprise to those familiar with the notorious “revolving door” in Brussels between the GMO industry and the regulatory body entrusted with making independent decisions on the risks of GMO in the EU, that EFSA condemned the Seralini study results. Most telling however of the brazen pro-GMO industry bias of EFSA’s GMO Panel members was the fact that the final ruling statement by the EFSA GMO Panel reviewing Seralini’s results announced, “Serious defects in the design and methodology of a paper by Séralini et al. mean it does not meet acceptable scientific standards and there is no need to re-examine previous safety evaluations of genetically modified maize NK603.” [21]

The EFSA is not the only source of blatant and reckless pro-GMO sentiment in Brussels. Some weeks before release of the embarrassing Seralini study, Anne Glover, chief scientific adviser of the EU Commission, said in an interview on 24 July, 2012, “There is no substantiated case of any adverse impact on human health, animal health or environmental health, so that’s pretty robust evidence, and I would be confident in saying that there is no more risk in eating GMO food than eating conventionally farmed food.” She added that the precautionary principle also no longer applies, which means the EU should not err on the side of caution on the approval of GMOs.[22]

Were there any pretense of scientific responsibility in the clearly corrupt EFSA panel, or Professor Glover’s office, they would have immediately called for multiple, independent similar long-term rat studies to confirm or disprove the Seralini results. They and the Monsanto GMO lobby influencing them clearly had no desire to do anything but try to slander the Seralini group with vague accusations and hope the obedient international media would take the headline and close the embarrassing story. It was typical of the entire history of the spread of patented GMO seeds and paired toxic herbicides like Roundup.

Notes:

[1] Seralini et al., Op. Cit.

[2] Ibid.

[3] WiseGeek, Why are Rats used in Animal Testing?, accessed in http://www.wisegeek.org/why-are-rats-used-in-animal-testing.htm

[4] Ibid.

[5] Ibid.

[6] Gilles-Eric Seralini et al, Genetically modified crops safety assessments: present limits and possible improvements, Environmental Sciences Europe 2011, 23:10, accessed in http://www.enveurope.com/content/23/1/10.

[7] Ibid.

[8] Aris, A., Leblanc, S., Maternal and fetal exposure to pesticides associated to genetically modified foods in Eastern Townships of Quebec, Canada, Reproductive Toxicology, 2011 May;31(4):528-33. Epub 2011 Feb 18.

[9] European Food Safety Authority (EFSA), Scientific Opinion of the Panel on Genetically Modified Organisms on applications (EFSA-GMO-NL-2005-22 and EFSA-GMO-RX-NK603) for the placing on the market of the genetically modified glyphosate tolerant maize NK603 for cultivation, food and feed uses and import and processing, and for renewal of the authorisation of maize NK603 as existing product, The EFSA Journal (2009) 1137, 1-50.

[10] Ibid.

[11] Ibid.

[12] GMO-Kompass, Food Safety Evaluation–Evaluating Safety: A Major Undertaking, February 15, 2006, accessed in http://www.gmo-compass.org/eng/safety/human_health/41.evaluation_safety_gm_food_major_undertaking.html

[13] Ibid.

[14] EFSA, Séralini et al. study conclusions not supported by data, says EU risk assessment community, EFSA Press Release, 28 November 2012, accessed in http://www.efsa.europa.eu/en/press/news/121128.htm

[15] Corporate Europe Observatory, Op. Cit.

[16] Ibid.

[17] Corporate Europe Observatory,  Approving the GM potato: conflicts of interest, flawed science and fierce lobbying, CorporateEurope.org, November 7, 2011, accessed in http://corporateeurope.org/publications/approving-gm-potato-conflicts-in…

[18] ILSI, 2011 Annual Report, Board of Trustees, accessed in http://www.ilsi.org/Documents/ILSI_AR2011_rFinal.pdf

[19] Tore B. Krudtaa, Harry Kuiper Chair of EFSA GMO panel – Another regulator in the business of deregulation?, Monsanto.No, 22 September 2011, accessed in http://www.monsanto.no/index.php/en/environment/gmo/gmo-news/166-harry-kuiper-chair-of-efsa-gmo-panel-another-regulator-in-the-business-of-deregulation

[20] EFSA, FAQ on the resignation of Diana Banati as member and Chair of EFSA´s Management Board, accessed in  http://www.efsa.europa.eu/en/faqs/faqresignationdianabanati.htm

[21] EFSA, Séralini et al. study conclusions not supported by data, says EU risk assessment community, EFSA Press Release, 28 November 2012, accessed in http://www.efsa.europa.eu/en/press/news/121128.htm.

[22] EurAktiv.com, GMOs: “Anne Glover, you are wrong,” 27 July 2012, accessed in http://www.euractiv.com/cap/gmos-anne-glover-wrong-analysis-514185

________________________________________________________________________________________________________________________

GLOBAL RESEARCH PUBLISHERS

Order William Engdahl’s Book directly from Global Research

  • seeds_2.jpg
Seeds of Destruction: Hidden Agenda of Genetic Manipulation
Author Name:
F. William Engdahl
ISBN Number:
978-0-937147-2-2
Year:
2007
Pages:
341 pages with complete index
List Price: $24.95
Special Price: $17.00

The Next Seven States To Legalize Pot

posted in: Cannabis News 0

USA — The Berlin Wall of pot prohibition seems to be crumbling before our eyes.

By fully legalizing marijuana through direct democracy, Colorado and Washington have fundamentally changed the national conversation about cannabis. As many as 58 percent of Americans now believe marijuana should be legal. And our political establishment is catching on. Former president Jimmy Carter came out this month and endorsed taxed-and-regulated weed. “I’m in favor of it,” Carter said. “I think it’s OK.” In a December 5th letter to Attorney General Eric Holder, Senate Judiciary Chairman Patrick Leahy (D-Vermont) suggested it might be possible “to amend the Federal Controlled Substances Act to allow possession of up to one ounce of marijuana, at least in jurisdictions where it is legal under state law.” Even President Obama hinted at a more flexible approach to prohibition, telling 20/20′s Barbara Walters that the federal government was unlikely to crack down on recreational users in states where pot is legal, adding, “We’ve got bigger fish to fry.”

Encouraged by the example of Colorado and Oregon, states across the country are debating the merits of treating marijuana less like crystal meth and more like Jim Beam. Here are the next seven states most likely to legalize it:

1) Oregon

Oregon could have produced a trifecta for pot legalization on election day. Like Washington and Colorado, the state had a marijuana legalization bid on the ballot in 2012, but it failed 54-46. The pro-cannabis cause was dogged by poor organization: Advocates barely qualified the initiative for the ballot, and could not attract billionaire backers like George Soros and Peter Lewis, who helped bankroll the legalization bit in Washington.

But given that Oregon’s biggest city, Portland, will be just across the Columbia River from prevalent, legal marijuana, the state legislature will be under pressure to create a framework for the drug’s legal use in Oregon – in particular if the revenue provisions of Washington’s law are permitted to kick in and lawmakers begin to watch Washington profit from the “sin taxes” on Oregon potheads. If lawmakers stall, state voters will likely have the last word soon enough. Consider that even cannabis-crazy Colorado failed in its first legalization bid back in 2006.

“We have decades of evidence that says prohibition does not work and it’s counterproductive,” said Peter Buckley, co-chair of the Oregon state legislature’s budget committee. For Buckley, it’s a matter of dollars and common sense: “There’s a source of revenue that’s reasonable that is rational that is the right policy choice for our state,” he said. “We are going to get there on legalization.”

2) California

California is unaccustomed to being a follower on marijuana liberalization. Its landmark medical marijuana initiative in 1996 sparked a revolution that has reached 18 states and the District of Columbia. And the artful ambiguity of that statute has guaranteed easy access to the drug — even among Californians with minor aches and pains.

In 2010, the state appeared to be on track to fully legalize and tax pot with Proposition 19. The Obama administration warned of a crackdown, and the state legislature beat voters to the punch with a sweeping decriminalization of pot that treats possession not as a misdemeanor but an infraction, like a parking ticket, with just a $100 fine. In a stunningly progressive move, that law also applies to underage smokers. And removing normal teenage behavior from the criminal justice system has contributed to a staggering decline in youth “crime” in California of nearly 20 percent in 2011.

The grandaddy of less-prohibited pot is again a top candidate to fully legalize cannabis. Prop 19 failed 53-47, and pot advocates are determined not to run another initiative in an “off-year” election, likely putting ballot-box legalization off for four years. “2016 is a presidential election year, which brings out more of the youth vote we need,” said Amanda Reiman, who heads up the Drug Policy Alliance’s marijuana reform in California.

Economics could also force the issue sooner. Eager for new tax revenue, the state legislature could seek to normalize the marijuana trade. There’s no Republican impediment: Democrats now have a supermajority in Sacramento, and Governor Brown has forcefully defended the right of states to legalize without the interference of federal “gendarmes.”

3) Nevada

Whether it’s gambling or prostitution, Nevada is famous for regulating that which other states prohibit. When it comes to pot, the state has already taken one swing at legalization in 2006, with an initiative that failed 56-44. “They got closer than we did in Colorado that year,” says Mason Tvert, who co-chaired Colorado’s initiative this year and whose first statewide effort garnered just 41 percent of the vote.

For prominent state politicians, the full legalization, taxation and regulation of weed feels all but inevitable. “Thinking we’re not going to have it is unrealistic,” assemblyman Tick Segerblom of Las Vegas said in November. “It’s just a question of how and when.”

4) Rhode Island

Pot watchers believe little Rhode Island may be the first state to legalize through the state legislature instead of a popular referendum. ”I’m hoping this goes nowhere,” one prominent opponent in the state House told the Boston Globe. ”But I think we’re getting closer and closer to doing this.”

Back in June 2012, lawmakers in Providence jumped on the decriminalization bandwagon, replacing misdemeanor charges for adult recreational use with a civil fine of $150. (Youth pay the same fine but also have to attend a drug education class and perform community service.)

In the wake of Colorado and Washington’s new state laws, Rhode Island has joined a slate of New England states that are vowing to vote on tax-and-regulate bills. A regulated marijuana market in Rhode Island could reap the state nearly $30 million in new tax revenue and reduced law enforcement costs. ”Our prohibition has failed,” said Rep. Edith Ajello of Providence, who is sponsoring the bill. ”Legalizing and taxing it, just as we did to alcohol, is the way to do it.”

5) Maine

Maine’s legislature has recently expanded decriminalization and is moving on a legalization-and-regulation bill that could bring the state $8 million a year in new revenue. ”The people are far ahead of the politicians on this,” said Rep. Diane Russell of Portland. ”Just in the past few weeks we’ve seen the culture shift dramatically.”

State legislators in Maine, as in other direct-democracy states, are actually wary of the ballot initiative process and may work to preempt the voters. A legalization scheme devised by lawmakers, after all, is likely to produce tighter regulation and more revenue than a bill dreamed up by pot consumers themselves.

6) Alaska

Alaska is already a pothead’s paradise, and the state could move quickly to bring order to its ambiguous marijuana law. Cannabis has been effectively legal in Alaska since 1975, when the state supreme court, drawing on the unique privacy protections of the Alaska constitution, declared that authorities can’t prohibit modest amounts of marijuana in the home of state residents.

That gave Alaskans the right to have up to four ounces – and 24 plants – in their homes. Following a failed bid to fully legalize pot at the ballot box in 2004 (the measure fell 56-44), the state legislature attempted to enforce prohibition, outlawing all weed in 2006. But citing the 1975 precedent, a judge later ruled the home exemption must be respected, though she sought to limit legal possession to a single ounce.

If taxation and regulation take root in nearby Washington, and perhaps more important in neighboring British Columbia (where legalization is also being considered), a ballot initiative in Alaska could win in an avalanche.

7) Vermont

Last year, Vermont finally normalized its medical marijuana law, establishing a system of government-sanctioned dispensaries. In November, the state’s Democratic governor, Peter Shumlin, just cruised to re-election while strongly backing marijuana decriminalization. The city of Burlington, meanwhile, passed a nonbinding resolution in November calling for an end to prohibition – with 70 percent support. The Green Mountain State has already embraced single-payer universal health care. Legal pot cannot be far behind.

Source: Rolling Stone (US)
Author: Tim Dickinson
Published: December 18, 2012
Copyright: 2012 Straight Arrow Publishers Company, L.P.
Contact: [email protected]
Website: http://www.rollingstone.com/

1 24 25 26 27 28 29 30 41